MEETING AGENDA ADVISORY COMMITTEE ON THE MEDICAL USES OF ISOTOPES

April 16-17, 2012 Two White Flint North Building (T2-B3), Rockville, Maryland

NOTE: Sessions of the meeting may be closed pursuant to 5 U.S.C. 552(b) to discuss organizational and personnel matters that relate solely to internal personnel rules and practices of the ACMUI; information the release of which would constitute a clearly unwarranted invasion of personal privacy; information the premature disclosure of which would be likely to significantly frustrate implementation of a proposed agency action; and disclosure of information which would risk circumvention of an agency regulation or statute.

Monday, April 16, 2012 CLOSED SESSION

8:00 – 10:45 **1. Commission Meeting Preparation**ACMUI members will prepare for the upcoming Commission Meeting.

		OPEN SESSION
10:45 – 11:00	2.	Opening Statements Mr. Einberg will formally open the meeting. C. Einberg, NRC
11:00 - 11:30	3.	Old Business Ms. Cockerham will review past ACMUI recommendations and provide NRC responses.
11:30 – 12:00	4.	Fundamental Concepts in Patient Advocacy Ms. Weil will provide a discussion on the fundamental concepts in patient advocacy.
12:00 - 1:30		LUNCH
1:30 - 2:00	5.	Electronic Signatures Subcommittee B. Thomadsen, ACMUI Dr. Thomadsen will provide a discussion on electronic signatures for medical records.
2:00 – 3:00	6.	Medical Events Subcommittee Report Dr. Welsh will discuss the subcommittee report on medical events for fiscal year 2011.
3:00 – 3:30	7.	Permanent Implant Brachytherapy Mr. Fuller will provide an update on proposed regulatory changes related to permanent implant brachytherapy programs.
3:30 - 4:00		BREAK
4:00 – 4:30	8.	Status of Commission Paper on Patient Release Dr. Daibes will provide an update on the status of the Commission paper for data collection regarding patient release.
4:30 - 5:00	9.	Radiation Therapy Implications from Anomalous Variations of the Nuclear Decay Law Dr. Welsh will provide a discussion on the relationship between anomalous variations of the Nuclear Decay Law and radiation therapy.

Tuesday, April 17, 2012 OPEN SESSION			
8:00 – 8:30	10.	Medical Use of Radium-223 Chloride A representative from the manufacturer will provide an overview of the clinical and radiation safety aspects of the medical use of Radium-223 chloride	
8:30 - 10:00	11.	Medical Use of Radium-223 Chloride P. Zanzonico, ACMUI Dr. Zanzonico will discuss the regulatory aspects of the medical use of Radium-223 chloride.	
10:00 - 10:30		BREAK	
10:30 - 11:00	12.	Strontium/Rubidium Update – NRC Perspective Dr. Howe will provide an update on the strontium breakthrough with rubidium-82 generators from an NRC perspective.	
11:00 – 11:30	13.	Strontium/Rubidium Update – FDA Perspective Dr. Suleiman will provide an update on the strontium breakthrough with rubidium-82 generators from an FDA perspective.	
11:30 -12:00	14.	Administrative Closing Ms. Holiday will provide a meeting summary and propose dates for the next meeting.	

12:00 ADJOURN